. . . with only 2,000 new cases of ocular melanoma in the US each year, would selumetinib be eligible for that special status and pricing? . . .
Then AZN will need to stick with uveal melanoma. However, they are going to start a phase 3 trial in K-Ras mutated NSCLC, which is a much broader indication.
But would it be possible to get orphan status to treat UM, and then have it withdrawn if the drug is ultimately approved for treating other, more common cancers?